Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Information provided by (Responsible Party):
Dey Identifier:
First received: July 21, 2010
Last updated: May 17, 2013
Last verified: May 2013
This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Fluticasone Propionate/Formoterol Fumarate
Drug: Formoterol Fumarate
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Pharmacodynamic Response of Fluticasone Propionate in Fixed-Dose Combination With Formoterol Fumarate in Subjects With COPD

Resource links provided by NLM:

Further study details as provided by Dey:

Primary Outcome Measures:
  • Change in forced expiratory volume at one second (FEV1) measured in milliliters by spirometry to assess pharmacodynamic response of fluticasone propionate in combination with formoterol fumarate in subject with COPD [ Time Frame: 12 Weeks ]

Secondary Outcome Measures:
  • Incidence of adverse events (AEs) [ Time Frame: 12 Weeks ]

Enrollment: 468
Study Start Date: August 2010
Study Completion Date: October 2011
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Fluticasone Propionate/Formoterol Fumarate
Inhalation Suspension
Experimental: 2 Drug: Fluticasone Propionate/Formoterol Fumarate
Inhalation Suspension
Experimental: 3 Drug: Fluticasone Propionate/Formoterol Fumarate
Inhalation Suspension
Experimental: 4 Drug: Fluticasone Propionate/Formoterol Fumarate
Inhalation Suspension
Experimental: 5 Drug: Fluticasone Propionate/Formoterol Fumarate
Inhalation Suspension
Active Comparator: 6 Drug: Formoterol Fumarate
Inhalation Solution
Placebo Comparator: 7 Drug: Placebo
Inhalation Solution


Ages Eligible for Study:   40 Days and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to understand the requirements of the study and provide written informed consent
  • A clinical diagnosis of COPD
  • A current or prior history of at least 10-pack years of cigarette smoking
  • Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the screening visit and agree to avoid becoming pregnant for the duration of study

Exclusion Criteria:

  • A clinical diagnosis of Asthma
  • Other significant disease than COPD
  • Subjects who radiation or chemotherapy within the previous 12 months
  • Subjects who had any lung resection
  • QTcB greater than 0.460 seconds
  • History of illegal drug abuse or alcohol abuse within the past 5 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01168310

  Show 23 Study Locations
Sponsors and Collaborators
  More Information

Responsible Party: Dey Identifier: NCT01168310     History of Changes
Other Study ID Numbers: 191-090
Study First Received: July 21, 2010
Last Updated: May 17, 2013

Keywords provided by Dey:
Pulmonary, Obstructive, lungs, COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Formoterol Fumarate
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017